Background
Patients with haematological malignancies often experience severe thrombocytopenia due to their disease or its treatment, leading to a high risk of bleeding. Platelet transfusions are commonly used to manage this risk, but their effectiveness is increasingly questioned. The TREATT trial explores the potential of tranexamic acid (TXA), an anti-fibrinolytic drug, to reduce bleeding and the reliance on platelet transfusions in these patients.
Study Design and Methods
The TREATT trial is a multinational, randomized, double-blind, placebo-controlled study conducted in Australia and the UK. Participants are adults with haematological malignancies undergoing treatment expected to cause significant thrombocytopenia. They are randomly assigned to receive TXA or a placebo, with treatment starting within 24 to 72 hours of a platelet count dropping to 30 × 10^9/L or below and continuing for up to 30 days.
Primary and Secondary Outcomes
The primary outcome measures the proportion of participants who die or experience WHO grade 2 or higher bleeding within the first 30 days of treatment. Secondary outcomes include the number of platelet and red cell transfusions, quality of life, and safety outcomes such as thrombotic events and mortality rates.
Significance
The trial addresses the need for effective strategies to minimize bleeding in high-risk patients, potentially reducing the burden on healthcare resources. By evaluating the cost-effectiveness of TXA, the study also aims to provide valuable insights into the economic implications of its use in clinical practice.
Conclusion
The TREATT trial represents a significant step forward in the management of thrombocytopenia in patients with haematological malignancies. Its findings could lead to a paradigm shift in the prevention and treatment of bleeding, offering a safer and more cost-effective alternative to platelet transfusions.
